慢性肾脏病4-5D期骨质疏松诊治:从消极到务实的转变
欧洲肾脏协会-欧洲透析与移植协会(ERA-EDTA)CKD-MBD工作组与国际骨质疏松基金会科学顾问委员会合作发布立场文件,针对CKD 4-5D期(eGFR < 30 ml/min/1.73 m2)患者骨质疏松的诊断与管理提出推荐。本文总结该2021年文件的主要推荐,涵盖诊断、骨折风险因素、风险评估、药物干预阈值、一般与药物管理、治疗监测及照护体系,倡导务实个体化诊疗以替代当前治疗消极态度。
要点
- CKD 4-5D期骨质疏松诊断需结合影像与临床评估。
- 脆性骨折风险因素与风险评估应纳入常规管理。
- 药物干预阈值与个体化治疗可替代消极态度。
核心结论
- 对CKD 4-5D期骨质疏松患者应采取务实个体化诊断与治疗,替代治疗消极态度。
研究设计与样本
- ERA-EDTA CKD-MBD工作组与国际骨质疏松基金会科学顾问委员会合作发布的立场文件总结。
主要发现
- 文件综述了CKD 4-5D期患者骨质疏松的诊断、脆性骨折风险因素、骨折风险评估、药物干预阈值、一般与药物管理、治疗监测及照护体系。
关键数值与推荐
- CKD 4-5D期定义为eGFR < 30 ml/min/1.73 m2。
临床怎么用
- 临床医生可依据该文件对CKD 4-5D期骨质疏松患者进行务实个体化的诊断与治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) CKD-MBD working group, in collaboration with the Committee of Scientific Advisors of the International Osteoporosis Foundation, published a position paper for the diagnosis and management of osteoporosis in patients with CKD stages 4-5D (eGFR < 30 ml/min 1.73 m2). The present article reports and summarizes the main recommendations included in this 2021 document. The following areas are reviewed: diagnosis of osteoporosis; risk factors for fragility fractures; fracture risk assessment; intervention thresholds for pharmacological intervention; general and pharmacological management of osteoporosis; monitoring of treatment, and systems of care, all in patients with CKD stages 4-5D. Guidance is provided for clinicians caring for CKD stages 4-5D patients with osteoporosis, allowing for a pragmatic individualized diagnostic and therapeutic approach as an alternative to current variations in care and treatment nihilism.
引用
- Evenepoel P, Cunningham J, Ferrari S, et al. Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. Osteoporos Int. 2021. PMID: 34129059. doi:10.1007/s00198-021-05975-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。